| 1. |
|
|
| 2. |
|
|
| 3. |
- Schwan, Sofie, et al.
(author)
-
A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system
- 2010
-
In: European Journal of Clinical Pharmacology. - : Springer Science and Business Media LLC. - 0031-6970 .- 1432-1041. ; 66:9, s. 947-953
-
Journal article (peer-reviewed)abstract
- Pregabalin is a gamma-aminobutyric acid (GABA) analogue approved for the treatment of epilepsy, neuropathic pain and generalised anxiety disorder. As a GABA analogue, there has been some concern about an abuse liability. We aimed to investigate the possible abuse liability of pregabalin. By applying a Bayesian data-mining algorithm to reports of possible drug abuse or addiction in the Swedish national register of adverse drug reactions (SWEDIS), we calculated the information component (IC) for pregabalin and reports of abuse and addiction. Out of 198 reports indicative of abuse or addiction to any drug, 16 concerned pregabalin. The IC became significantly elevated in the fourth quarter of 2008, rising to 3.99 (95% confidence interval 3.21-4.59) at the end of 2009. Based on the signal from the present study, we conclude that pregabalin is likely to be associated with an abuse potential.
|
|
| 4. |
- Schwan, Sofie, et al.
(author)
-
Escitalopram kontra citalopram vid egentlig depression : Översikt av studier visar inget stöd för kliniskt relevant skillnad i effekt
- 2009
-
In: Läkartidningen. - 0023-7205 .- 1652-7518. ; 106:12, s. 858-861
-
Journal article (peer-reviewed)abstract
- Escitalopram har påståtts ha bättre effekt än citalopram. Det påstås även att detta konsekvent är visat i kliniska studier. En analys av publicerade randomiserade studier som jämförde escitalopram och citalopram beträffande effekten vid egentlig depression gjordes. Avsikten var att undersöka om kliniskt relevanta skillnader har visats. Tillgängliga publicerade data har högt bevisvärde för slutsatsen att det inte finns någon kliniskt relevant skillnad i effekt mellan escitalopram och citalopram.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Schwan, Sofie, et al.
(author)
-
Ranking antidepressants
- 2009
-
In: The Lancet. - 0140-6736 .- 1474-547X. ; 373:9677, s. 1761-1761
-
Journal article (peer-reviewed)
|
|
| 10. |
|
|
